HUP0204281A2 - Eljárás glukagonszerű peptid-1 vegyületek szolubiliázálására - Google Patents

Eljárás glukagonszerű peptid-1 vegyületek szolubiliázálására

Info

Publication number
HUP0204281A2
HUP0204281A2 HU0204281A HUP0204281A HUP0204281A2 HU P0204281 A2 HUP0204281 A2 HU P0204281A2 HU 0204281 A HU0204281 A HU 0204281A HU P0204281 A HUP0204281 A HU P0204281A HU P0204281 A2 HUP0204281 A2 HU P0204281A2
Authority
HU
Hungary
Prior art keywords
glp
compound
solution
sulubilizing
glucagon
Prior art date
Application number
HU0204281A
Other languages
English (en)
Inventor
Walter Francis Prouty
Joseph Vincent Rinella
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0204281A2 publication Critical patent/HUP0204281A2/hu
Publication of HUP0204281A3 publication Critical patent/HUP0204281A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Abstract

A találmány tárgya eljárás vizes oldatban pH 7,4-en GLP-1 vegyületelőállítására, mely annak a GLP-1 vegyületnek felel meg, melyalapvetően pH = 7,4-en vizes oldatban oldhatatlan. Az oldhatatlan GLP-1 vegyületet a GLP-1 oldat kialakításához vizes lúgban vagy vizesbázisban feloldják. A GLP-1 oldatot ezek után olyan pH-rasemlegesítik, melyen a GLP-1 vegyület aminosav racemizációjalényegében nem megy végbe, majd az oldható GLP-1 vegyületet asemlegesített oldatból elkülönítik. Ó
HU0204281A 2000-01-27 2001-01-16 Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds HUP0204281A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17843800P 2000-01-27 2000-01-27
US22405800P 2000-08-09 2000-08-09
PCT/US2001/000010 WO2001055213A2 (en) 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 (glp-1) compounds

Publications (2)

Publication Number Publication Date
HUP0204281A2 true HUP0204281A2 (hu) 2003-04-28
HUP0204281A3 HUP0204281A3 (en) 2007-03-28

Family

ID=26874307

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204281A HUP0204281A3 (en) 2000-01-27 2001-01-16 Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds

Country Status (17)

Country Link
US (4) US7598222B2 (hu)
EP (1) EP1257577B1 (hu)
JP (1) JP2003523366A (hu)
KR (1) KR20020073184A (hu)
AT (1) ATE264870T1 (hu)
AU (1) AU2001232735A1 (hu)
BR (1) BR0107837A (hu)
CA (1) CA2396920A1 (hu)
DE (1) DE60102899T2 (hu)
DK (1) DK1257577T3 (hu)
ES (1) ES2218381T3 (hu)
HU (1) HUP0204281A3 (hu)
IL (2) IL150913A0 (hu)
MX (1) MXPA02007231A (hu)
PT (1) PT1257577E (hu)
TR (1) TR200401142T4 (hu)
WO (1) WO2001055213A2 (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
CA2518465A1 (en) * 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2004087910A1 (ja) * 2003-03-28 2004-10-14 National Institute Of Agrobiological Sciences 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
ES2375056T3 (es) * 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
EP2292254A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
AU2004265341A1 (en) * 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ES2727854T3 (es) * 2003-11-20 2019-10-21 Novo Nordisk As Formulaciones de péptidos que contienen propilenglicol que son óptimas para la producción y para su uso en dispositivos de inyección
CN102140090A (zh) * 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
US7820676B2 (en) 2004-08-23 2010-10-26 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
BRPI0517341A (pt) 2004-11-12 2008-10-07 Novo Nordisk As composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
JP4828432B2 (ja) 2004-11-19 2011-11-30 三井化学株式会社 エチレン系重合体微粒子、官能基含有エチレン系重合体微粒子およびその製造用触媒担体
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
JP5252915B2 (ja) 2005-04-07 2013-07-31 三井化学株式会社 オレフィン系重合体からなるカプセル状の微粒子
PE20070622A1 (es) * 2005-09-14 2007-08-22 Takeda Pharmaceutical Administracion de inhibidores de dipeptidil peptidasa
MY159522A (en) * 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
CA2621806C (en) 2005-09-14 2016-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EA015169B1 (ru) 2005-09-14 2011-06-30 Такеда Фармасьютикал Компани Лимитед Применение ингибиторов дипептидилпептидазы
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) * 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
ATE507235T1 (de) 2006-02-08 2011-05-15 Lonza Ag Synthese von glucagon-ähnlichen peptiden
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100029941A1 (en) * 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR20090088854A (ko) * 2006-09-13 2009-08-20 다케다 야쿠힌 고교 가부시키가이샤 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20210027546A (ko) 2009-06-12 2021-03-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
CN105102427B (zh) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 含有环状酰亚胺的肽产物的合成
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10308677B2 (en) 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US9969769B2 (en) 2014-12-19 2018-05-15 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
AU2018321157B2 (en) 2017-08-24 2024-03-28 Novo Nordisk A/S GLP-1 compositions and uses thereof
EP3728303A1 (en) * 2017-12-19 2020-10-28 Novo Nordisk A/S Solubility of glp-1 peptide
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
WO2022266927A1 (zh) * 2021-06-24 2022-12-29 深圳翰宇药业股份有限公司 一种利拉鲁肽变构体及其制备方法、应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3419824A1 (de) * 1984-05-26 1985-11-28 Bayer Ag, 5090 Leverkusen Verfahren und formwerkzeug zum herstellen von formteilen mit grill-, gitter- oder rostartigen bereichen, wie kfz-soft-faces, spoiler, bumper, aus einer fliessfaehigen masse
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue

Also Published As

Publication number Publication date
ATE264870T1 (de) 2004-05-15
US8268780B2 (en) 2012-09-18
IL150913A0 (en) 2003-02-12
WO2001055213A3 (en) 2002-02-28
KR20020073184A (ko) 2002-09-19
US20130072658A1 (en) 2013-03-21
PT1257577E (pt) 2004-08-31
BR0107837A (pt) 2003-01-14
EP1257577A2 (en) 2002-11-20
JP2003523366A (ja) 2003-08-05
US20030060412A1 (en) 2003-03-27
DE60102899D1 (de) 2004-05-27
HUP0204281A3 (en) 2007-03-28
US8222205B2 (en) 2012-07-17
US20110053838A1 (en) 2011-03-03
US20120208980A1 (en) 2012-08-16
US7598222B2 (en) 2009-10-06
US20120101034A9 (en) 2012-04-26
DK1257577T3 (da) 2004-08-02
EP1257577B1 (en) 2004-04-21
TR200401142T4 (tr) 2004-07-21
AU2001232735A1 (en) 2001-08-07
DE60102899T2 (de) 2005-03-31
WO2001055213A2 (en) 2001-08-02
ES2218381T3 (es) 2004-11-16
US8455433B2 (en) 2013-06-04
IL189371A0 (en) 2008-06-05
MXPA02007231A (es) 2002-12-09
CA2396920A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
HUP0204281A2 (hu) Eljárás glukagonszerű peptid-1 vegyületek szolubiliázálására
JOP20180046B1 (ar) متراكبات قابلة للذوبان في الماء من حديد وكربوهيدرات، إنتاجها وأدوية تحتوي عليها
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
ITMI20020908A1 (it) Processo di preparazione di sodio alendronato
YU2003A (sh) Stabilne soli o-acetilsalicilne kiseline sa baznim amino-kiselinama
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
NZ515301A (en) Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
SE0002202D0 (sv) New peptides
ATE443082T1 (de) Insulinvorstufen und verfahren zu deren herstellung
GEP20053650B (en) Disinfectant Solution Based on Sodium Hypochlorite, and Process for Preparing It
AR026030A1 (es) Un complejo a base de acido ortosilicico biologicamente asimilable, que se presenta bajo una forma solida, estable y concentrada, y un proceso depreparacion de dicho complejo
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
ATE377000T1 (de) 5-ht1f agonisten
EP0891966A3 (en) Method for industrial purification of capsaicin
AR009582A1 (es) Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato
IT1319674B1 (it) Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
DE69104220T2 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
RS63804A (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
DE69522702D1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
Eda et al. Peptidyl human heart chymase inhibitors. 1. Synthesis and inhibitory activity of difluoromethylene ketone derivatives bearing P′ binding subsites
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
WO2000073540A8 (de) Verfahren zur herstellung einer cyanidfreien, für galvanische gold-bäder geeigneten goldverbindungslösung
PE20000271A1 (es) Composicion farmaceutica de (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenteno-1-metanol
WO2001075095A1 (fr) Procede de production de proteine de recombinaison

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal